Amyris Stock Forecast, Price & News

Amyris (NASDAQ:AMRS) Frequently Asked Questions

Is Amyris a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Amyris stock.
View analyst ratings for Amyris or view top-rated stocks.

How has Amyris' stock price been impacted by Coronavirus?

Amyris' stock was trading at $2.96 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization. Since then, AMRS stock has increased by 65.9% and is now trading at $4.91.
View which stocks have been most impacted by COVID-19.

When is Amyris' next earnings date?

Amyris is scheduled to release its next quarterly earnings announcement on Tuesday, March 1st 2022.
View our earnings forecast for Amyris.

How were Amyris' earnings last quarter?

Amyris, Inc. (NASDAQ:AMRS) released its quarterly earnings data on Monday, November, 8th. The biotechnology company reported ($0.11) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.15) by $0.04. The biotechnology company had revenue of $47.90 million for the quarter, compared to analysts' expectations of $64.21 million. Amyris's quarterly revenue was up 39.7% compared to the same quarter last year. During the same period in the previous year, the firm earned ($0.41) earnings per share.
View Amyris' earnings history.

When did Amyris' stock split? How did Amyris' stock split work?

Shares of Amyris reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

What guidance has Amyris issued on next quarter's earnings?

Amyris updated its FY 2021 earnings guidance on Monday, December, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $330 million-$370 million.

What price target have analysts set for AMRS?

4 brokers have issued twelve-month price targets for Amyris' stock. Their forecasts range from $15.00 to $30.00. On average, they anticipate Amyris' stock price to reach $22.00 in the next twelve months. This suggests a possible upside of 348.1% from the stock's current price.
View analysts' price targets for Amyris or view top-rated stocks among Wall Street analysts.

Who are Amyris' key executives?

Amyris' management team includes the following people:

• John G. Melo, President, Chief Executive Officer & Director (LinkedIn Profile)
• Eduardo Alvarez, Chief Operating Officer (LinkedIn Profile)
• Han Kieftenbeld, Chief Financial & Administration Officer
• Sunil Chandran, Senior Vice President-Research & Development
• Charles Kraft, SVP-Global Manufacturing & Process Development

What is John Melo's approval rating as Amyris' CEO?

53 employees have rated Amyris CEO John Melo on Glassdoor.com. John Melo has an approval rating of 54% among Amyris' employees. This puts John Melo in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Amyris' key competitors?

Some companies that are related to Amyris include Marathon Petroleum (MPC), Phillips 66 (PSX), Valero Energy (VLO), HollyFrontier (HFC), Renewable Energy Group (REGI), CVR Energy (CVI), PBF Energy (PBF), World Fuel Services (INT), Green Plains (GPRE), Clean Energy Fuels (CLNE), Delek US (DK), Gevo (GEVO), REX American Resources (REX) and Adams Resources & Energy (AE).
View all of AMRS's competitors.

What other stocks do shareholders of Amyris own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Advanced Micro Devices (AMD), Sorrento Therapeutics (SRNE), Nokia (NOK), Gevo (GEVO), Inovio Pharmaceuticals (INO), Pfizer (PFE), AT&T (T), Dynavax Technologies (DVAX), Novavax (NVAX) and NVIDIA (NVDA).

What is Amyris' stock symbol?

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Who are Amyris' major shareholders?

Amyris' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Lattice Capital Management LLC (0.00%), IFP Advisors Inc (0.00%), MJP Associates Inc. ADV (0.00%), Endurance Wealth Management Inc. (0.00%) and Cutler Group LP (0.00%). Company insiders that own Amyris stock include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, James F Mccann, John Melo, L John Doerr and Nicole Kelsey.
View institutional ownership trends for Amyris.

Which institutional investors are selling Amyris stock?

AMRS stock was sold by a variety of institutional investors in the last quarter, including Cutler Group LP. Company insiders that have sold Amyris company stock in the last year include Anthony Hughes, Eduardo Alvarez, Frank Kung, Hermanus Kieftenbeld, John Melo, and Nicole Kelsey.
View insider buying and selling activity for Amyris or view top insider-selling stocks.

Which institutional investors are buying Amyris stock?

AMRS stock was bought by a variety of institutional investors in the last quarter, including Lattice Capital Management LLC, MJP Associates Inc. ADV, Endurance Wealth Management Inc., and IFP Advisors Inc. Company insiders that have bought Amyris stock in the last two years include Frank Kung, James F Mccann, and L John Doerr.
View insider buying and selling activity for Amyris or or view top insider-buying stocks.

How do I buy shares of Amyris?

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Amyris' stock price today?

One share of AMRS stock can currently be purchased for approximately $4.91.

How much money does Amyris make?

Amyris has a market capitalization of $1.51 billion and generates $173.14 million in revenue each year. The biotechnology company earns $-331.04 million in net income (profit) each year or ($1.95) on an earnings per share basis.

How many employees does Amyris have?

Amyris employs 595 workers across the globe.

When was Amyris founded?

Amyris was founded in 2003.

What is Amyris' official website?

The official website for Amyris is amyris.com.

Where are Amyris' headquarters?

Amyris is headquartered at 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608.

How can I contact Amyris?

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at (510) 450-0761, via email at [email protected], or via fax at 510-225-2645.